v3.26.1
Segment Reporting - Summary of Expense Categories Reviewed (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting Information [Line Items]    
Research and development $ (70,873) $ (10,130)
General and administrative (13,787) (10,328)
Net loss (78,865) (17,983)
Segments    
Segment Reporting Information [Line Items]    
Unallocated research and development and other [1] (3,574) (796)
General and administrative [2] (4,417) (3,586)
Personnel related (including stock-based compensation) [3] (20,844) (11,001)
Interest income 5,716 1,675
Other income (expense), net 79 800
Net loss (78,865) (17,983)
Segments | Ribupatide injection    
Segment Reporting Information [Line Items]    
Research and development [4] (50,571) (4,469)
Segments | KAI-7535    
Segment Reporting Information [Line Items]    
Research and development [4] (4,483) (374)
Segments | KAI-4729    
Segment Reporting Information [Line Items]    
Research and development [4] (410) (232)
Segments | Ribupatide oral    
Segment Reporting Information [Line Items]    
Research and development [4] $ (361) $ 0
[1] Unallocated research and development includes external costs that are not program specific primarily related to consultant and contractor costs, in addition to research and development allocated rent expense and depreciation.
[2] General and administrative includes external costs related to the Company’s executive, finance, legal, and other administrative functions, such as professional fees for legal, patent, consulting, accounting, audit and tax services. General and administrative also includes information technology costs and general and administrative allocated rent expense and depreciation.
[3] Internal costs includes salaries and related costs, including stock-based compensation, for employees.
[4] External research and development is allocated to the Company’s programs, and includes nonclinical, clinical trial, contract manufacturing, non-employee consultant and contractor, and other research and development costs.